Key clinical point: Researchers identified potential prognostic markers and targets for treatment in patients with non–small cell lung cancer (NSCLC) and brain metastases.

Major finding: PI3K signaling was significantly associated with an increased risk of brain metastases, and the researchers found “potential druggable mutations” in CDKs and PIK3CA.

Study details: Retrospective study of matched primary tumor and brain metastases samples from 61 Chinese patients with NSCLC.

Disclosures: The National Natural Science Foundation of China and the Natural Science Foundation of Guangdong Province supported the research. The researchers disclosed relationships with Geneseeq Technology Inc. in Toronto and Nanjing Geneseeq Technology Inc.